Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
This study examines the relationship between menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer, focusing on whether associations differ according to whether the tumors arein situ or invasive. Data are from a prospective study conducted 1980–89 on 49,017 selected participants in the Breast Cancer Detection Demonstration Project, a five-year screening program conducted between 1973 and 1980 in the United States. Overall, the rate ratio for estrogen-only use compared with no-hormone use was 1.0, and that for the estrogen-progestin combination was 1.2 (95 percent confidence interval [CI]=1.0–1.6). However, the associations differed according to whether the tumors werein situ or invasive. The rate ratios ofin situ breast cancer associated with use of estrogens alone and the combination regimen were 1.4 (CI=1.0–2.0) and 2.3 (CI=1.3–3.9), respectively. Duration of estrogen-only use also was associated with risk ofin situ tumors, with users for 10 or more years at twice the risk of nonusers (P-value for trend test =0.02). Duration of use was not associated with risk of in vaisve cancer. Our results are consistent with the hypothesis that hormone replacement therapy is related to earlier-stage breast cancer; however, the possibility that the results reflect increased breast cancer surveillance among those taking hormones cannot be ruled out.
- Merz B. Pharmaceutical list tracks hit parade of prescriptions.Am Med News 1991;34: 4.
- Harris RB, Laws A, Reddy VM, King A, Haskell W. Are women using postmenopausal estrogen? A community survey.Am J Public Health 1990;80: 1266–8.
- Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of non-contraceptive estrogens and progestins in the United States, 1974–86.Am J Public Health 1988;78: 1478–81.
- Kaufman DW, Miller DR, Rosenberg L, et al. Non-contraceptive estrogen use and the risk of breast cancerJAMA 1984;252: 63–7.
- Brinton LA, Hoover RN, Fraumeni JF Jr. Menopausal estrogens and breast cancer risk: an expanded case-control study.Br J Cancer 1986;54a: 825–32.
- Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy.JAMA 1987;257: 209–15.
- Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark.Int J Cancer 1988;42: 832–8.
- Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement.N Engl J Med 1989;321: 293–7.
- Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: results from the Toronto breast cancer study.Am J Epidemiol 1991;134: 1386–95.
- Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Noncontraceptive hormone use and risk of breast cancer.Cancer Causes Control 1992;3: 475–9.
- Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study.Cancer Causes Control 1991;3: 433–9.
- Hulka BS, Chambless LE, Deubner DC, Wilkinson WE. Breast cancer and estrogen replacement therapy.Am J Obstet Gynecol 1982;143: 638–44.
- McDonald JA, Weiss NS, Daling JR, Francis AM, Polissar L. Menopausal estrogen use and the risk of breast cancer.Breast Cancer Res Treat 1986;7: 193–9.
- Nomura AMY, Kolonel LN, Hirohata T, Lee J. The association of replacement estrogens with breast cancer.Int J Cancer 1986;37: 49–53.
- Mills PK, Beeson J, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in seventh-day adventists.Cancer 1989;64: 591–7.
- Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer.JAMA 1980;243: 1635–9.
- Hoover R, Glass A, Finkle WD, Azevedo D, Milne K. Conjugated estrogens and breast cancer risk in women.JNCI 1981;67: 815–20.
- Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy.Br J Obstet and Gynaecol 1987;94: 620–35.
- Kaufman DW, Palmer JR, de Mouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study.Am J Epidemiol 1991;134: 1375–85.
- Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems.Obstet Gynecol 1979;54: 74–9.
- Gambrell RD, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users.Obstet Gynecol 1983;62: 435–43.
- Risch HA, Howe GR. Menopausal hormone use and breast cancer in Saskatchewan: a record-linkage cohort study.Am J Epidemiol 1994;139: 670–83.
- King RJB. A discussion of the roles of estrogen and progestin in human mammary carcinogenesis.J Steroid Biochem Molec Biol 1991;39: 811–8.
- Masters JRW, Drife JO, Scarisbrick JJ. Cyclic variation of DNA synthesis in human breast epithelium.JNCI 1977;58: 1263–5.
- Ferguson DJP, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the ‘resting’ human breast.Br J Cancer 1981;44: 177–81.
- Anderson TJ, Ferguson DJP, Raab GM. Cell turnover in the ‘resting’ human breast: influence of parity, contraceptive pill, age and laterality.Br J Cancer 1982;46: 376–82.
- Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle.Am J Surg Pathol 1986;10: 382–93.
- Going JJ, Anderson TJ, Battersby S, Macintyre CCA. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles.Am J Pathol 1988;130: 193–204.
- Potten CS, Watson RJ, Williams GT, et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast.Br J Cancer 1988;58: 163–70.
- Habel LA, Stanford JL. Hormone receptors and breast cancer.Epidemiol Rev 1993;15: 209–19.
- Tinnemans JGM, Beex LVAM, Wobbles TH, Sluis RF, Raemaekers JMM, Benraad TH. Steroid-hormone receptors in nonpalpable and more advanced stages of breast cancer.Cancer 1990;66; 1165–7.
- Helin HJ, Helle MJ, Kallioniemi O-P, Isola JJ. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma.Cancer 1989;63: 1761–7.
- Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer.Acta Oncol 1988;27: 1–19.
- Brinton LA, Hoover RN, Szklo M, Fraumeni JF. Menopausal estrogen use and risk of breast cancer.Cancer 1981;47: 2517–22.
- Goodman MT, Nomura AMY, Wilkens LR, Kolonel LN. Agreement between interview information and physician records on history of menopausal estrogen use.Am J Epidemiol 1990;131: 815–25.
- Rosai J. Borderline epithelial lesions of the breast.Am J Surg Pathol 1991;15: 209–21.
- Rosen PP. Proliferative breast ‘disease’: an unresolved dilemma.Cancer 1993;71: 3798–807.
- Schnitt SJ, Silen W, Sadowsky NL, Connolly JL, Harris JR. Ductal carcinoma in situ (intraductal carcinomas of the breast).N Engl J Med 1988;318: 898–903.
- Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)
Cancer Causes & Control
Volume 5, Issue 6 , pp 491-500
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- Breast cancer
- hormone replacement therapy
- United States
- Industry Sectors
- Author Affiliations
- 1. Environmental Epidemiology Branch, National Cancer Institute, Betbesda, MD, USA
- 3. Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA